Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.

You may also be interested in...

End Of The 'March-In' Pricing Petitions?

KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.

NIH Resists “March In” On Norvir Patents Based On Pricing Concerns

NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.

Abbott's Kaletra Promotions Overstate Length Of Efficacy, FDA Says

A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts